Are Wall Street Analysts Bullish on Globe Life’s Stock?

Barchart
在Barchart上打开
Are Wall Street Analysts Bullish on Globe Life’s Stock?

Globe Life Inc. (GL) is a McKinney, Texas-headquartered insurance holding company serving primarily middle-income customers. Its operations span life insurance, supplemental health insurance, and investments, with products distributed through exclusive and independent agents and direct-to-consumer channels. The company has a market capitalization of $12.02 billion.

Over the past 52 weeks, the stock has increased 20.9%, and it is up 14% year-to-date (YTD) because investors have rewarded its steady premium growth, higher investment income, and aggressive capital returns. The stock reached a 52-week high of $191.55 on July 17 but is down 16.8% from that level. 

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Meanwhile, the broader S&P 500 Index ($SPX) has gained 10.1% and 8.3% over the same periods, respectively, indicating the stock has outperformed the broader market over these periods. Next, we compare the stock with its own sector. The State Street Financial Select Sector SPDR ETF (XLF) is up 10.9% over the past 52 weeks and 6.2% YTD. Therefore, the stock has outperformed its sector over the past year.

www.barchart.com

Investors did not welcome Globe Life’s third-quarter results, as the company reported a 4% year-over-year (YOY) drop in net operating income to $378.84 million as it incurred more interest on debt; while its per-share value increased from $4.81 to $4.84, it missed Wall Street analysts’ expectations.  

Globe Life reduced its full-year 2026 net operating income guidance to $15.35-$15.65 per diluted share, down from $15.55-$15.95 previously. The company cited a roughly $16 million underwriting loss at Evry Health and about $7 million in excess Medicare Supplement claims caused by CMS processing delays.

For the current quarter, Wall Street analysts expect Globe Life’s diluted EPS to grow 6.2% YOY to $3.60. Moreover, EPS is expected to increase 6.6% annually to $15.48 in fiscal 2026, then increase 5.9% to $16.39 in fiscal 2027. However, the company has missed consensus estimates in each of the four trailing quarters.

Among the 15 Wall Street analysts covering Globe Life’s stock, the consensus is a “Moderate Buy.” That’s based on seven “Strong Buy” ratings, two “Moderate Buys,” and six “Holds.” The ratings mix has become less bullish than a month ago, with “Strong Buy” ratings down from eight to seven.

www.barchart.com

Piper Sandler downgraded Globe Life’s stock last month from “Overweight” to “Neutral” and lowered the price target from $200 to $165. Piper Sandler expects continued volatility from higher medical-claim severity, even with reinsurance limiting major downside risk. It attributes the pressure to rising costs for cancer, heart disease, and other serious medical events.

Globe Life’s mean price target of $184.93 indicates a 16% upside over current market prices. Moreover, the Street-high price target of $218 implies a 36.8% upside. 


On the date of publication, Anushka Dutta did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Nvidia’s Leadership Crisis Could Be a Major Opportunity for AMD Stock McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. Ahead of Target Earnings, Here's What Barchart Data Says Comes Next for TGT Stock Dear Lowe’s Stock Fans, Mark Your Calendars for November 18